Stock Events

Stock Events

Innate Pharma 

€1.2260
104
+€0.01+0.82%Friday 07:00

Statistics

Day High
1.226
Day Low
1.226
52W High
2.16
52W Low
1.054
Volume
0
Avg. Volume
46
Mkt Cap
136.94M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

Sep 17Expected
Q4 2025
Q2 2026
-0.31
-0.27
-0.24
-0.21
Expected EPS
-0.25374460389000003
Actual EPS
-0.20896614438

Financials

-1,764.51%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
2.79MRevenue
-49.18MNet Income

Analyst Ratings

$6.07Average Price Target
The highest estimate is ⁦6.83⁩.
From 2 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow IDD.MU. It's not an investment recommendation.
TotalEnergies
23
TTE.PA
Stellantis N.V
15
STLAP.PA
Credit Agricole.
14
ACA.PA
Axa
13
CS.PA

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Bristol-Myers Squibb
BMY
Mkt Cap127.71B
Bristol-Myers Squibb competes in the immuno-oncology space, offering products that could be in direct competition with Innate Pharma's pipeline, particularly in cancer treatment.
Merck
MRK
Mkt Cap368.89B
Merck is known for its strong presence in cancer treatment with Keytruda, competing directly with Innate Pharma's oncology focus.
Roche
RHHBY
Mkt Cap334.28B
Roche operates in similar therapeutic areas as Innate Pharma, including oncology, making it a direct competitor in the development of cancer therapies.
Astrazeneca
AZN
Mkt Cap289.48B
AstraZeneca competes in the oncology sector, including collaborations on drugs that could be in competition with Innate Pharma's developments.
Pfizer
PFE
Mkt Cap173.95B
Pfizer has a broad oncology portfolio that competes with Innate Pharma's cancer treatment and research efforts.
Gilead Sciences
GILD
Mkt Cap211.7B
Gilead Sciences, with its focus on oncology and inflammatory diseases, competes in areas of interest to Innate Pharma.
Novartis
NVS
Mkt Cap303.67B
Novartis has a significant presence in the oncology market, directly competing with Innate Pharma's research and drug development.
AMGEN
AMGN
Mkt Cap251.94B
Amgen's focus on innovative therapeutics in oncology and other areas makes it a competitor to Innate Pharma.
Regeneron Pharmaceuticals
REGN
Mkt Cap95.99B
Regeneron Pharmaceuticals competes in the biopharmaceutical space, focusing on oncology and other areas relevant to Innate Pharma's interests.
Incyte
INCY
Mkt Cap24.54B
Incyte operates in the oncology and inflammation sectors, directly competing with Innate Pharma in the development of treatments for cancer and autoimmune diseases.

About

Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. The company's approach includes therapeutic modalities such as monoclonal antibodies, multispecific NK cell engagers through its ANKET platform, and antibody-drug conjugates (ADC). Its portfolio includes lacutamab, which is being studied for cutaneous T-cell lymphomas and peripheral T-cell lymphomas, and monalizumab, which is being developed in collaboration with AstraZeneca for non-small cell lung cancer. The company's revenue mainly consists of revenues from collaboration and licensing agreements and government financing for research expenditure in the form of research tax credits, as well as other grants.
Show More
CEO
Jonathan E. Dickinson
Employees
163
Country
France
ISIN
FR0010331421
WKN
000A0LCUJ

Listings

XETRA
DE
IDD.XETRA
STU
DE
IDDA.STU
STU
DE
IDD.STU
LSE
GB
0EVI.LSE

0 Comments

Share your thoughts

FAQs

What is Innate Pharma stock price today?▼
The current price of IDD.MU is €1.23 EUR — it has increased by +0.82% in the past 24 hours. Watch Innate Pharma stock price performance more closely on the chart.
What is Innate Pharma stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Muenchen exchange Innate Pharma stocks are traded under the ticker IDD.MU.
Is Innate Pharma stock price growing?▼
IDD.MU stock has fallen by -5.84% compared to the previous week, the month change is a -8.1% fall, over the last year Innate Pharma has showed a -20.7% decrease.
What is Innate Pharma market cap?▼
Today Innate Pharma has the market capitalization of 136.94M
When is the next Innate Pharma earnings date?▼
Innate Pharma is going to release the next earnings report on March 25, 2027.
What were Innate Pharma earnings last quarter?▼
IDD.MU earnings for the last quarter are -0.21 EUR per share, whereas the estimation was -0.25 EUR resulting in a +17.65% surprise. The estimated earnings for the next quarter are N/A EUR per share.
What is Innate Pharma revenue for the last year?▼
Innate Pharma revenue for the last year amounts to 2.79M EUR.
What is Innate Pharma net income for the last year?▼
IDD.MU net income for the last year is -49.18M EUR.
How many employees does Innate Pharma have?▼
As of November 8, 2026, the company has 163 employees.
In which sector is Innate Pharma located?▼
Innate Pharma operates in the Health & Wellness sector.
When did Innate Pharma complete a stock split?▼
Innate Pharma has not had any recent stock splits.
Where is Innate Pharma headquartered?▼
Innate Pharma is headquartered in Marseille, France.